FDA Clearance Tracker · P180002-S022
Zephyr Valve Reigstry (ZEVR)
Last checked: Nov 20, 2026Latest source record: Mar 25, 2023 (this decision)Source: openFDAMethods & limitations
Decided
Mar 25, 2023
Approved
Time to decision
30 days
Received Feb 23, 2023. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track No User Fee
Device class
Class III
The decision
- FDA number
- P180002-S022
- Device name
- Zephyr Valve Reigstry (ZEVR)
- Applicant
- Pulmonx Corporation
- Applicant location
- Redwood City, CA
- Received
- Feb 23, 2023
- Decided
- Mar 25, 2023
- Decision
- Approved
- Supplement type
- Normal 180 Day Track No User Fee
- Reason for supplement
- Postapproval Study Protocol
- Original approval
- P180002
Device type
- Device type
- Valve, pulmonary (NJK)
- Device class
- Class III
- Specialty
- Anesthesiology & Respiratory
FDA's approval statement
As written in FDA's record.
Approval for modifications to the protocol including an increase in study sites from 10 to 15 and minor clarification changes.
Source documents
Other decisions for Pulmonx Corporation
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K253096 · Decided Feb 13, 2026 · 143 days after receipt
Device type: Tube, Tracheal/Bronchial, Differential Ventilation (W/Wo Connector) (CBI) · Anesthesiology & Respiratory
4 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.